Description
COVID-19 drugs must be manufactured under good manufacturing practices (GMP) conditions. These conditions must be in line with the international requirements outlined in the International Council for Harmonization Q7A guideline and with applicable Health Canada's guidance.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements | HTML | Open resource | |
| Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements | HTML | Open resource |